Analysts Set GoodRx Holdings, Inc. (NASDAQ:GDRX) Target Price at $4.14

GoodRx Holdings, Inc. (NASDAQ:GDRX) has been assigned a consensus rating of “Hold” from the thirteen research firms that are covering the firm, Marketbeat reports. Three investment analysts have rated the stock with a sell recommendation, six have given a hold recommendation and four have issued a buy recommendation on the company. The average 12 month price target among brokerages that have updated their coverage on the stock in the last year is $4.1364.

A number of research analysts recently weighed in on GDRX shares. UBS Group lifted their target price on shares of GoodRx from $2.50 to $3.75 and gave the company a “neutral” rating in a research note on Thursday. Wells Fargo & Company increased their price target on GoodRx from $3.50 to $5.00 and gave the stock an “overweight” rating in a research note on Friday, August 7th. Leerink Partners set a $5.00 price target on GoodRx in a report on Thursday, August 6th. Wall Street Zen upgraded GoodRx from a “hold” rating to a “buy” rating in a research report on Saturday. Finally, TD Cowen boosted their price objective on GoodRx from $4.00 to $5.00 and gave the company a “buy” rating in a research report on Tuesday, August 11th.

GoodRx Price Performance

NASDAQ GDRX opened at $3.73 on Friday. GoodRx has a 12 month low of $1.77 and a 12 month high of $5.81. The stock has a market cap of $1.28 billion, a price-to-earnings ratio of 93.27, a PEG ratio of 1.77 and a beta of 1.60. The company’s 50 day moving average is $3.03 and its two-hundred day moving average is $2.59. The company has a current ratio of 1.38, a quick ratio of 1.38 and a debt-to-equity ratio of 0.74.

GoodRx (NASDAQ:GDRX) last posted its quarterly earnings results on Wednesday, August 5th. The company reported $0.08 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.08. The business had revenue of $200.41 million during the quarter, compared to analyst estimates of $193.23 million. GoodRx had a net margin of 2.07% and a return on equity of 7.22%. The company’s revenue was down 1.3% on a year-over-year basis. During the same period in the prior year, the business posted $0.09 earnings per share. As a group, research analysts anticipate that GoodRx will post 0.16 earnings per share for the current year.

Institutional Trading of GoodRx

Several institutional investors and hedge funds have recently added to or reduced their stakes in GDRX. Quarry LP bought a new stake in shares of GoodRx during the third quarter valued at approximately $33,000. Cetera Investment Advisers bought a new position in shares of GoodRx during the second quarter worth $50,000. Boothbay Fund Management LLC bought a new position in shares of GoodRx during the third quarter worth $43,000. Meridian Wealth Management LLC bought a new stake in GoodRx in the 4th quarter valued at $29,000. Finally, Shay Capital LLC bought a new stake in GoodRx in the 3rd quarter valued at $47,000. Institutional investors own 63.77% of the company’s stock.

GoodRx Company Profile

GoodRx Holdings, Inc (NASDAQ: GDRX) operates a digital healthcare platform designed to help consumers compare prescription drug prices at retail pharmacies across the United States. Through its website and mobile applications, GoodRx aggregates pricing and discount information from a wide network of pharmacies, enabling users to access coupons and savings programs on both generic and brand-name medications. The platform also features price transparency tools that inform patients about cost variations and available discounts to alleviate the financial burden of prescription medications.

In addition to its core drug pricing service, GoodRx offers telehealth services under the GoodRx Care brand, providing virtual consultations for a range of non-emergency conditions and prescription needs.